65214-84-8

Usage

Ethyl ester derivative

1-Piperidinecarboxylic acid, 4-(diphenylmethoxy)-, ethyl ester is an ethyl ester, meaning it has an ethoxy group (C2H5O) attached to the piperidinecarboxylic acid.

Interaction with the central nervous system

1-Piperidinecarboxylic acid, 4-(diphenylmethoxy)-, ethyl ester may interact with the central nervous system, which could make it a potential therapeutic agent.

Building block for the synthesis of pharmaceuticals

1-Piperidinecarboxylic acid, 4-(diphenylmethoxy)-, ethyl ester can be used as a building block for the synthesis of other pharmaceuticals and drugs, making it a valuable tool in drug development.

Potential therapeutic applications

1-Piperidinecarboxylic acid, 4-(diphenylmethoxy)-, ethyl ester may have potential therapeutic applications, although the exact uses and efficacy may depend on the specific application and formulation.

Upstream product

• 147-20-6 diphenylpyraline 
• 541-41-3 chloroformic acid ethyl ester 
• 65214-82-6 4-hydroxy-piperidine-1-carboxylic acid ethyl ester 
• 776-74-9 Bromodiphenylmethane 

Downstream Products

• 65214-86-0 4-(diphenylmethoxy)piperidine hydrochloride 
• 770685-45-5 6-(4-Benzhydryloxy-piperidin-1-yl)-hexanoic acid methyl ester 
• 661481-71-6 5-(4-Benzhydryloxy-piperidin-1-yl)-pentanoic acid ethyl ester 
• 133016-99-6 ethyl 3-[4-(diphenylmethoxy)piperidin-1-yl]propanoate 
• 133015-42-6 ethyl <(4-diphenylmethoxy)piperidino>acetate 
• 133993-23-4 4-(4-Benzhydryloxy-piperidin-1-yl)-butyric acid 
• 125602-76-8 ethyl 4-(4-benzhydryloxypiperidino)butanoate 
• 58258-01-8 4-diphenylmethoxypiperidine 

Relevant academic research and scientific papers

Treatment of CNS disorders using CNS target modulators

The invention is directed to compositions and methods useful for treating Central Nervous System (CNS) disorders. Furthermore, the invention provides compositions and methods of treating sleep disorders. More specifically, the invention is directed to the compositions and use of derivatized, histamine antagonists for the treatment of sleep disorders.

TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS

The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.

Triazolo and derivatives as chemokine inhibitors

Novel triazolo derivatives represented by the following formula and pharmaceutically acceptable salts thereof, as well as chemokine inhibitors containing the same as an effective component. These are useful as therapeutic agents for allergic diseases such

Amphoteric drugs. I. Synthesis and antiallergic activity of [4-(diphenylmethoxy)piperidino]-, [4-(diphenylmethyl)piperazinyl]- and [4-(diphenylmethylene)piperidino]alkanoic acid derivatives

A simple method of transforming classical antihistaminics into nonsedative antiallergic agents with strong effects in rat models is described. Various [4-(diphenylmethoxy)piperidinol - (series A), [4-(diphenylmethyl)piperazinyl]- (series B) and [4-(diphenylmethylene)piperidino]alkanoic acid derivatives (series C) were synthesized and examined for antiallergic activities and effects on the central nervous system (CNS), in comparison with the corresponding N-methyl derivatives (1a-c). N-Alkylcarboxylic acids (5a-c) showed stronger inhibitory effects on compound 48/80-induced lethality in rats than the corresponding N-methyl derivatives (1a-c). In particular, N-alkylcarboxylic acids (5a) in series A exhibited approximately 100-fold stronger inhibitory effects than 1a, and were the least effective in prolonging the sleeping time on hexobarbital-induced anesthesia in mice in all series. As a result of chemical modification in series A, it was found that introduction of a methyl group at the para-position on one benzene ring in the (diphenylmethoxy)piperidine system effectively reduced CNS side-effects without reducing antiallergic activity. (+)-3-[4-[(4-Methylphenyl)phenylmethoxy] piperidinol propionic acid ((+)-51), an optically active isomer of 51, exhibited a stronger antiallergic effect (ED50 = 0.17 mg/kg, p.o.) than ketotifen and terfenadine in the 48 h homologous passive cutaneous anaphylaxis (PCA) test, and moreover exhibited no CNS side-effects, such as prolongation of the sleeping time on hexobarbital-induced anesthesia, at an oral dose of 30 mg/kg. Compound (+)-51 was thus proved to be a promising candidate as a nonsedative antiallergic agent.

1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives

Novel 1-[(heterocyclyl)alkyl]-4-diarylmethoxy piperidine derivatives are disclosed having the formula STR1 where n is 2-6, Ar1 and Ar2 are aryl and B is a substituted benzimidazolyl radical. These compounds are useful for their antianaphylactic and antihistaminic properties. Specific claimed compounds are 1-{3-[4-(diphenylmethoxy)-1-piperidinyl]-propyl}-1,3-dihydro-2H-benzimidazol-2-one, 1-{2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl}1-, 3-dihydro-2H-benzimidazol-2-one, and 1-{4-[4-(diphenylmethoxy)-1-piperidinyl]butyl}-1,3-dihydro-2H-benzimidazol-2-one.